



Model List of Essential Medicines



Alprostadil (prostaglandin E1) [General information](#)

Section

Medicines administered to the neonate [c]

- Parenteral > General injections > IV: 0.5 mg per mL in alcohol

Indications

[Other specified congenital anomaly of great arteries including arterial duct](#)



Beractant [General information](#)

Section

Medicines administered to the neonate [c]

- Respiratory > Suspension: 25 mg per mL for intratracheal instillation

Indications

[Respiratory distress syndrome of newborn](#)



Caffeine citrate [General information](#)

Section

Medicines administered to the neonate [c]

- Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
- Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)

Indications

[Apnoea of newborn](#)



Carbetocin [General information](#)

Section

Uterotonics

- Parenteral > General injections > IV: 100 µg per mL (heat stable)

Indications

[Postpartum haemorrhage](#)



Chlorhexidine [General information](#)

Section

Medicines administered to the neonate [c]

- Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
- Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)

Indications

[Omphalitis of newborn](#)



Clomifene [General information](#)

Section

Ovulation inducers

- Oral > Solid: 50 mg (citrate)

Indications

[Female infertility without specification whether primary or secondary](#)

☐

Condoms [General information](#)

Section

Barrier methods

- -

Indications

[Contact with health services for contraceptive management](#)

☐

Copper-containing intrauterine device [General information](#)

Section

Intrauterine devices

- -

Indications

[Contact with health services for insertion of contraceptive device](#)

☐

Dexamethasone [General information](#)

Section

Other medicines administered to the mother

- Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))

Indications

[Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy](#)

☐

Diaphragms [General information](#)

Section

Barrier methods

- -

Indications

[Contact with health services for contraceptive management](#)

☐

Dinoprostone (prostaglandin E2) [General information](#)

Section

Medicines administered to the neonate [c]

- Parenteral > General injections > IV: 1 mg per mL

Indications

[Other specified congenital anomaly of great arteries including arterial duct](#) Therapeutic equivalent to [alprostadil \(prostaglandin E1\)](#) for [Other specified congenital anomaly of great arteries including arterial duct](#)

☐

Ergometrine [General information](#)

Section

Uterotonics

- Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)

Indications

[Postpartum haemorrhage](#)

☐

Estradiol cypionate + medroxyprogesterone acetate [General information](#)

Section

Injectable hormonal contraceptives

- Parenteral > General injections > IM: 5 mg + 25 mg

Indications

[Contact with health services for reasons associated with reproduction](#)

☐

Ethinylestradiol + etonogestrel [General information](#)

Section

Intravaginal contraceptives

- Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg

Indications

[Contact with health services for contraceptive management](#)



Ethinylestradiol + levonorgestrel [General information](#)

Section

Oral hormonal contraceptives

- Oral > Solid: 50 µg + 250 µg [4]
- Oral > Solid: 30 µg + 150 µg

Indications

[Contact with health services for postcoital contraception](#) [Contact with health services for contraceptive management](#)



Ethinylestradiol + norethisterone [General information](#)

Section

Oral hormonal contraceptives

- Oral > Solid: 35 µg + 1 mg

Indications

[Contact with health services for contraceptive management](#)



Etonogestrel-releasing implant [General information](#)

Section

Implantable contraceptives

- Implant > Subdermal: 68 mg single rod

Indications

[Contact with health services for insertion of contraceptive device](#)



Ibuprofen [General information](#)

Section

Medicines administered to the neonate [c]

- Parenteral > General injections > IV: 5 mg per mL

Indications

[Patent arterial duct](#)



Indometacin [General information](#)

Section

Medicines administered to the neonate [c]

Indications

Therapeutic equivalent to [ibuprofen](#) for [Patent arterial duct](#)



Letrozole [General information](#)

Section

Ovulation inducers

- Oral > Solid > dosage form: 2.5 mg

Indications

[Female infertility without specification whether primary or secondary](#)



Levonorgestrel [General information](#)

Section

Oral hormonal contraceptives

- Oral > Solid: 750 µg [2]; 1.5 mg [1]
- Oral > Solid: 30 µg

Indications

[Contact with health services for postcoital contraception](#) [Contact with health services for contraceptive management](#)

Section

Intrauterine devices

- Intrauterine system with reservoir containing 52 mg of levonorgestrel.

Indications

[Contact with health services for insertion of contraceptive device](#)



Levonorgestrel-releasing implant [General information](#)

Section

Implantable contraceptives

- Implant > Subdermal: 75 mg per rod (two-rods)

Indications

[Contact with health services for insertion of contraceptive device](#)



Medroxyprogesterone acetate [General information](#)

Section

Injectable hormonal contraceptives

- Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
- Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system

Indications

[Contact with health services for reasons associated with reproduction](#)



Methylergometrine [General information](#)

Section

Uterotonics

Indications

Therapeutic equivalent to [ergometrine](#) for [Postpartum haemorrhage](#)



Mifepristone - misoprostol [General information](#)

Section

Medicines for medical abortion

- Oral > Solid > tablet: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package

Indications

[Unspecified time of fetal death, cause not specified Induced abortion](#)



Misoprostol [General information](#)

Section

Uterotonics

- Local > Vaginal > tablet: 25 µg
- Oral > Solid: 200 µg

Indications

[Unspecified obstetric condition Postpartum haemorrhage](#)

Section

Medicines for medical abortion

- Oral > Solid > tablet: 200 µg

Indications

[Spontaneous abortion, incomplete, without complication](#)



Multiple micronutrient supplement [General information](#)

Section

Other medicines administered to the mother

- Tablet containing:
- Vit A: 800 mcg retinol activity equivalent
- Vit C: 70 mg
- Vit D: 5 mcg (200 IU)
- Vit E: 10 mg alpha tocopherol equivalent
- Vit B1: 1.4 mg
- Vit B2: 1.4 mg
- Vit B3: 18 mg niacin equivalent
- Vit B6: 1.9 mg
- Folic acid: 400 mcg

- Vit B12: 2.6 mcg
- Iron: 30 mg
- Iodine: 150 mcg
- Zinc: 15 mg
- Selenium: 65 mcg
- Copper: 2 mg

Indications

[Maternal care for other specified conditions predominantly related to pregnancy](#)

☐

Nifedipine [General information](#)

Section

Antioxytocics (tocolytics)

- Oral > Solid: 10 mg (immediate-release)

Indications

[Preterm labour without delivery](#)

☐

Norethisterone [General information](#)

Section

Oral hormonal contraceptives

- Oral > Solid: 350 µg

Indications

[Contact with health services for contraceptive management](#)

☐

Norethisterone enantate [General information](#)

Section

Injectable hormonal contraceptives

- Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution

Indications

[Contact with health services for reasons associated with reproduction](#)

☐

Oxytocin [General information](#)

Section

Uterotonics

- Parenteral > General injections > unspecified: 10 IU per mL

Indications

[Postpartum haemorrhage](#)

☐

Porcatant alfa [General information](#)

Section

Medicines administered to the neonate [c]

- Respiratory > Suspension: 80 mg per mL for intratracheal instillation

Indications

[Respiratory distress syndrome of newborn](#)

☐

Progesterone vaginal ring [General information](#)

Section

Intravaginal contraceptives

- Local > Vaginal > vaginal ring: 2.074 g micronized progesterone

Indications

[Contact with health services for contraceptive management](#)

☐

Tranexamic acid [General information](#)

Section

Other medicines administered to the mother

- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

[Postpartum haemorrhage](#)

☐

Ulipristal [General information](#)

Section

Oral hormonal contraceptives

- Oral > Solid: 30 mg tablet (ulipristal acetate)

Indications

[Contact with health services for postcoital contraception](#)